Skip to main content

Peer Review reports

From: TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study

Original Submission
10 Dec 2023 Submitted Original manuscript
12 Jan 2024 Reviewed Reviewer Report
30 Jan 2024 Reviewed Reviewer Report
26 Feb 2024 Author responded Author comments - Feixiang Wu
Resubmission - Version 2
26 Feb 2024 Submitted Manuscript version 2
24 Apr 2024 Reviewed Reviewer Report
15 May 2024 Author responded Author comments - Feixiang Wu
Resubmission - Version 3
15 May 2024 Submitted Manuscript version 3
18 May 2024 Author responded Author comments - Feixiang Wu
Resubmission - Version 4
18 May 2024 Submitted Manuscript version 4
28 May 2024 Author responded Author comments - Feixiang Wu
Resubmission - Version 5
28 May 2024 Submitted Manuscript version 5
29 May 2024 Author responded Author comments - Feixiang Wu
Resubmission - Version 6
29 May 2024 Submitted Manuscript version 6
30 May 2024 Author responded Author comments - Feixiang Wu
Resubmission - Version 7
30 May 2024 Submitted Manuscript version 7
3 Jun 2024 Author responded Author comments - Feixiang Wu
Resubmission - Version 8
3 Jun 2024 Submitted Manuscript version 8
5 Jun 2024 Author responded Author comments - Feixiang Wu
Resubmission - Version 9
5 Jun 2024 Submitted Manuscript version 9
Publishing
6 Jun 2024 Editorially accepted
11 Jun 2024 Article published 10.1186/s12885-024-12484-3

You can find further information about peer review here.

Back to article page